EUVIMEDEUVIMED entdecken
MetaanalyseNetzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis

Yingying Luo iD, Jun Xia iD, Zhan Zhao iD, Yaping Chang iD, Yong Mong Bee iD, Khue Thy Nguyen iD, Soo Lim iD, Daisuke Yabe iD, Margaret McGill, Alice Pik Shan Kong iD, Siew Pheng Chan iD, Marisa Deodat iD und 9 weitere

Journal of Diabetes · 2023

DOI: 10.1111/1753-0407.13381 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Diabetes, 2023. Verfasst von Yingying Luo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sponsored by the Chinese Geriatric Endocrine Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins in insulin‐naïve patients with type 2 diabetes mellitus.

Methods

MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched from January 2000 to February 2022. The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines were followed and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was adopted. The registration ID is CRD42022319078 in PROSPERO.

Results

Among 11 163 citations retrieved, 35 publications met the planned criteria. From meta‐analyses and network meta‐analyses, we found that when injecting basal insulin regimens at bedtime, the optimal choice in order of most to least effective might be glargine U‐300 or degludec U‐100, glargine U‐100 or detemir, followed by neutral protamine hagedorn (NPH). Injecting glargine U‐100 in the morning may be more effective (ie, more patients archiving glycated hemoglobin < 7.0%) and lead to fewer hypoglycemic events than injecting it at bedtime. The optimal starting dose for the initiation of any basal insulins can be 0.10–0.20 U/kg/day. There is no eligible evidence to investigate the optimal maintenance dose for basal insulins.

Conclusions

The five basal insulins are effective for the target population. Glargine U‐300, degludec U‐100, glargine U‐100, and detemir lead to fewer hypoglycemic events than NPH without compromising glycemic control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaHumansHypoglycemic AgentsInsulinInsulin DetemirInsulin GlargineInsulin, IsophaneInsulin, Long-Acting

Stichwörter der Autor:innen

2型糖尿病basal insulineffectivenessinitiation and maintenance dosesafetysystematic reviewtype 2 diabetes基础胰岛素安全有效性系统评价起始和维持剂量

Substanzen

Hypoglycemic AgentsInsulinInsulin DetemirInsulin GlargineInsulin, IsophaneInsulin, Long-Acting

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
  • Nottingham Ningbo GRADE Centre, University of Nottingham Ningbo China, Ningbo, Zhejiang, 315100, China.
  • Academic Unit of Lifespan and Population Health, School of Medicine, The University of Nottingham, Nottingham, NG7 2UH, UK.
  • Tianjin Tiantian Biotechnology Co., Ltd., Tianjin, 300000, China.
  • OrthoEvidence Inc., Burlington, Ontario, L7N 3H8, Canada.
  • Department of Endocrinology, Singapore General Hospital, 169608, Singapore, Singapore.

ORCID-Profile: Yingying Luo, Jun Xia, Zhan Zhao, Yaping Chang, Yong Mong Bee, Khue Thy Nguyen, Soo Lim, Daisuke Yabe, Alice Pik Shan Kong, Siew Pheng Chan, Marisa Deodat, Chaicharn Deerochanawong, Ketut Suastika, Chenchen Xu, Liming Chen, Wei Chen, Xiaoying Li, Weigang Zhao, Xiaomei Yao, Linong Ji

Förderung

  • Sponsored by the Chinese Geriatric Endocrine Society

Zitieren

APA

Luo, Y., Xia, J., Zhao, Z., Chang, Y., Bee, Y. M., Nguyen, K. T., Lim, S., Yabe, D., McGill, M., Kong, A. P. S., Chan, S. P., Deodat, M., Deerochanawong, C., Suastika, K., Xu, C., Chen, L., Chen, W., Li, X., Zhao, W., …, & Ji, L. (2023). Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis. Journal of Diabetes. https://doi.org/10.1111/1753-0407.13381

Vancouver

Luo Y, Xia J, Zhao Z, Chang Y, Bee YM, Nguyen KT, et al. Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis. Journal of Diabetes. 2023. doi:10.1111/1753-0407.13381

BibTeX
@article{Luo2023,
  author = {Luo, Yingying and Xia, Jun and Zhao, Zhan and Chang, Yaping and Bee, Yong Mong and Nguyen, Khue Thy and Lim, Soo and Yabe, Daisuke and McGill, Margaret and Kong, Alice Pik Shan and Chan, Siew Pheng and Deodat, Marisa and Deerochanawong, Chaicharn and Suastika, Ketut and Xu, Chenchen and Chen, Liming and Chen, Wei and Li, Xiaoying and Zhao, Weigang and Yao, Xiaomei and Ji, Linong},
  title = {Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis},
  journal = {Journal of Diabetes},
  year = {2023},
  doi = {10.1111/1753-0407.13381}
}
Kostenlos starten →